论文部分内容阅读
米托蒽醌(Mitoxantron,Mx)是蒽环类抗肿瘤药物中一个新型的合成制剂,抗肿瘤谱类似阿霉素,但心脏毒性远低于后者,主要副作用为骨髓抑制和粘膜炎。主要用于治疗急性非淋巴细胞性白血病,近来国外报道用于治疗难治性非何杰金氏淋巴瘤(NHL),其有效率达45%。我们对2例使用多种化疗方案治疗无
Mitoxantron (Mox) is a new synthetic agent in anthracycline antineoplastic drugs. Its anticancer spectrum is similar to doxorubicin, but the cardiotoxicity is much lower than the latter. The main side effects are myelosuppression and mucositis. Mainly for the treatment of acute non-lymphocytic leukemia, recently reported for the treatment of refractory non-Hodgkin’s lymphoma (NHL), the effective rate of 45%. We treated 2 patients with multiple chemotherapy regimens